Ocular Therapeutix

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Ocular Therapeutix reports strong Q4 performance and eyes pivotal trials

Ocular Therapeutix delivered a strong performance in Q4 2022, showcasing revenue growth and advancements in key product developments.
While facing financial challenges and the need for strategic partnerships, the company's solid cash position and product pipeline offer opportunities for future growth.
Investors should monitor Ocular Therapeutix's progress in pivotal trials, commercial expansion, and potential alliances to assess its long-term growth prospects.

Ocular Therapeutix progresses on OTX-TKI program and boosts sales

Ocular Therapeutix showcased advancements in its OTX-TKI program and DEXTENZA sales growth, while addressing financial performance.
Positive clinical trial updates and pricing strategy enhancements position the company for future growth.
Challenges include lack of operational spend guidance and uncertainties in study timelines, with opportunities in trial outcomes and market expansion.

Ocular Therapeutix reports record revenue, navigates pivotal trial funding

Ocular Therapeutix (OCUL) achieved record revenue with DEXTENZA and made significant progress in pipeline development.
While facing financial challenges and operational complexities, the company's strategic initiatives and leadership additions position it for future growth.
Advancements in trial designs, FDA interactions, and funding strategies offer avenues for enhancing product development and commercialization.

Ocular Therapeutix reports strong Q3 revenue growth and advances AMD treatment

Ocular Therapeutix's Q3 performance reflects revenue growth driven by DEXTENZA, with a focus on advancing wet AMD treatment through the OTX-TKI program.
While facing challenges in R&D expenses and trial enrollment criteria, the company is well-positioned with funding options and strategic partnerships.
Opportunities lie in expanding DEXTENZA's market presence, achieving pipeline milestones, and leveraging funding avenues for future growth and innovation.

Ocular Therapeutix excels in retinal focus, poised for leadership

Ocular Therapeutix is on a positive trajectory with advancements in key studies and a strong financial position. The company faces competition and regulatory challenges but has the potential to lead in retinal disease treatment with its innovative approach.

Ocular Therapeutix excels in AXPAXLI trials with FDA support

Ocular Therapeutix's Q3 2024 Earnings Call highlighted strong performance in trial enrollment and FDA support for AXPAXLI trials, backed by promising prior study results.
With solid financial positioning, active commercial efforts, and a strategic trial design, Ocular shows potential for success in the competitive ophthalmic market.
While facing challenges in differentiation, regulatory submissions, and operational complexities, Ocular can leverage opportunities for market acceptance and revenue growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Ocular Therapeutix (OCUL) Q3 Earnings Expected to Decline

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced multiple scientific presentations at the American Academy of Ophthalmology (AAO) 2021 Annual Meeting being held November 12 -15, 2021. “We are happy to have a large presence at AAO this year with six poster presentations in five different indications,” said Mic

Ocular Therapeutix™ to Present Data at the American Academy of Ophthalmology (AAO) 2021 Virtual Annual Meeting

Agenus

Atea Pharmaceuticals

Novavax

Biotech stocks that fall hard on bad news can rebound in a flash.

Are Atea Pharmaceuticals, Agenus, Novavax, and Ocular Therapeutix Bad News Buy?

The company's experimental dry-eye treatment produced some disappointing clinical trial results.

Here's Why Ocular Therapeutix Stock Is Sinking Today

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (Nasdaq:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced topline results from its Phase 2 clinical trial of OTX-CSI (cyclosporine intracanalicular insert) for the treatment of dry eye disease (DED). The Phase 2, U.S.-based, randomized, double-masked, multi-center, vehicle-controlled clinical trial of OTX-CSI wa

Ocular Therapeutix™ Announces Topline Results for Phase 2 Clinical Trial of OTX-CSI for the Treatment of Dry Eye Disease Did Not Meet Primary Endpoint

Amyris

Renalytix AI plc

You can pick up small pieces of these great businesses for next to nothing.

3 Great Stocks You Can Buy With $50 Right Now

Axsome Therapeutics

Chemocentryx

These stocks are expected to put up big gains in a short amount of time.

3 Biotech Stocks That Could Rise 90% or More, According to Wall Street

The FDA has approved Ocular Therapeutix Inc's (NASDAQ: OCUL) supplemental application to broaden the Dextenza label. The approval now adds an indication for ocular itching associated with allergic conjunctivitis.

Why Are Ocular Therapeutix Shares Trading Higher Today?

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the U.S. Food and Drug Administration (FDA) has approved its Supplemental New Drug Application (sNDA) to broaden the DEXTENZA label to add an additional indication for the treatment of ocular itching associated with allergic conjunctivitis. With the appro

Ocular Therapeutix™ Announces FDA Approval of Supplemental New Drug Application (sNDA) for DEXTENZA® (dexamethasone ophthalmic insert) 0.4 mg for Intracanalicular Use for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations. Dr. Edwards will join the senior leadership team and be responsible for technical development, manufacturing, quality and supply chain operations. “We are excited to

Ocular Therapeutix™ Announces Appointment of Karen-Leigh Edwards as Senior Vice President of Technical Operations

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced the appointment of Merilee Raines to the Company's Board of Directors effective September 20, 2021. “We are excited to welcome Merilee to our Board of Directors,” said Antony Mattessich, President and Chief Executive Officer of Ocular Therapeutix. “Merile

Ocular Therapeutix™ Appoints Merilee Raines to Its Board of Directors

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported in-market unit sales of DEXTENZA® billable inserts of 6,924 and 9,321 in July and August, respectively, as part of the Company's corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference. August units represent the second highe

Ocular Therapeutix™ Updates Monthly In-Market Unit Sales of DEXTENZA® Billable Inserts

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held from September 13-15, 2021. In addition to the presentation, the management team will host virtual investor meetings. Investors participating in the conference

Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

When patients see more clearly, so too should investors.

This Exciting Biopharma Could Earn You 55% in 12 Months

This company's drug delivery technology just isn't getting the appreciation it deserves right now.

4 Reasons I Just Bought Ocular Therapeutix Stock

SmileDirectClub

Squarespace

Victoria's Secret & Co

Arcturus Therapeutics

Biohaven Pharmaceutical Hld

With the trading day more than halfway over, the broad markets were mixed yet again, but this came with a couple of record highs.

Tuesday Afternoon Analyst Upgrades and Downgrades: SmileDirectClub, Squarespace, Victoria's Secret and More

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will participate in two panels and will provide a pre-recorded presentation at the H.C. Wainwright Ophthalmology Virtual Conference being held on Tuesday, August 17th, 2021: Surpassing the Standard of Care for Glaucoma Panel Date: Tuesday, August

Ocular Therapeutix™ to Present at the H.C. Wainwright Ophthalmology Virtual Conference

Ocular Therapeutix, Inc. (OCUL) CEO Antony Mattessich on Q2 2021 Results - Earnings Call Transcript

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today reported financial results for the second quarter of 2021, and provided updates on its ophthalmology pipeline. “It has been a productive quarter for Ocular as we work to build a leading ophthalmology company,” said Antony Mattessich, President and Chief Executive O

Ocular Therapeutix™ Reports Second Quarter 2021 Financial Results and Business Update

OCUL has dropped substantially since a December 2020 stock offering.

Ocular Therapeutix: Why I'm Buying The Dip

Regeneron Pharmaceuticals

Ocular Therapeutix Inc (NASDAQ: OCUL) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) have terminated the option and license agreement collaboration. The termination is effective immediately.

Ocular Therapeutix, Regeneron Cull Aflibercept Agreement For Retinal Diseases

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that Regeneron has terminated the option and license agreement collaboration between the companies. The termination became effective August 5, 2021. The collaboration with Regeneron was initially formed in 2016 for the development and commercialization of

Ocular Therapeutix™ Announces Termination of the Collaboration with Regeneron to Develop a Sustained-Release Formulation of Aflibercept for the Treatment of Wet AMD and other Serious Retinal Diseases

Will Ocular Therapeutix (OCUL) Report Negative Earnings Next Week? What You Should Know

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it has dosed the first patient in the United States Phase 1 clinical trial of OTX-TKI (axitinib intravitreal implant) for the treatment of wet age-related macular degeneration (wet AMD). “We are very excited to have recently begun dosing patients in

Ocular Therapeutix™ Announces First Patient Dosed in U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet Age-Related Macular Degeneration

BEDFORD, Mass.--(BUSINESS WIRE)---- $OCUL #OCUTX--Ocular Therapeutix™, Inc. (Nasdaq: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report second quarter financial results on Monday, August 9, 2021. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:30 p.m. Eastern Ti

News for Ocular Therapeutix Stock (OCUL)